MoonLake Immunotherapeutics
MLTX
MLTX
136 hedge funds and large institutions have $2.34B invested in MoonLake Immunotherapeutics in 2025 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 31 increasing their positions, 43 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
5.92% less ownership
Funds ownership: 100.57% → 94.65% (-5.9%)
28% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 43
32% less capital invested
Capital invested by funds: $3.43B → $2.34B (-$1.09B)
Holders
136
Holding in Top 10
6
Calls
$21.1M
Puts
$8.78M
Top Buyers
| 1 | +$13.7M | |
| 2 | +$13.5M | |
| 3 | +$11.6M | |
| 4 |
VPC
Vestal Point Capital
New York
|
+$7.81M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$7.48M |
Top Sellers
| 1 | -$54.5M | |
| 2 | -$44.7M | |
| 3 | -$27.7M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$23.6M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$18M |
